English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

There are reports of Guillain-Barré syndrome (GBS) and cranial neuropathies occurring during or shortly after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.1,2 Some recent infections are known to trigger GBS. A recent epidemiologic cohort study found no evidence for causality between coronavirus disease 2019 (COVID-19) and GBS.3 There is a modest risk of GBS attributed to any vaccination (about 1 to 3 additional cases per million people vaccinated for seasonal influenza),4 and this has raised the possibility that the worldwide COVID-19 vaccination campaign may lead to some people developing GBS.5 Documents submitted to the Food and Drug Administration for Emergency Use Authorization of the Johnson & Johnson COVID-19 vaccine, d26.COV2.S, a recombinant, replication-incompetent adenovirus serotype 26 (Ad26) vector encoding a full-length and stabilized SARS-CoV-2 spike protein, however, include reports of 2 patients, 1 in the placebo and 1 in the active arm of the trial, developing GBS within 2 weeks of receiving an injection.6,7 Here we report the clinical features of the participant who received the vaccine (5 × 1010 viral particles) at the intended dose for clinical practice and discuss why this case cannot be used to establish a causal association between vaccination and the onset of GBS.

Guillain-Barré Syndrome in the Placebo and Active Arms of a COVID-19 Vaccine Clinical Trial